High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.

Breast Cancer Res · 2025 · PMC12337404 · PMID 40790765

Europe PMC DOI

hedged sentence

0.1210

closest p · 2.4× alpha

0.1210

boldest claim

The sentences

did not reach statistical significancep = 0.121not close (p > 0.1)

This finding did not reach statistical significance ( p = 0.121, Fisher’s Exact test), likely due to the limited number of patients achieving a pCR.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.